Gainers
OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.
Akeso Inc announced a collaboration and license agreement with Summit Therapeutics Inc (NASDAQ:SMMT) to out-license its breakthrough bispecific antibody, ivonescimab (PD-1/VEGF, AK112) for…
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced a definitive agreement of its partnership with Akeso Inc. (HKEX Code: 9926.HK, "Akeso"),